# Claims

1. A pharmaceutical composition comprising a combination of

(A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and

(B) an insulin secretagogue.

2. The pharmaceutical composition according to claim 1, wherein the insulin secretagogue is glipizide, glibenclamide, or glimepiride.

3. The pharmaceutical composition according to claim 2, wherein the insulin secretagogue is glipizide or glimepiride.

4. The pharmaceutical composition according to claim 2, wherein the insulin secretagogue is glipizide.

5. The pharmaceutical composition according to claim 2, wherein the insulin secretagogue is glimepiride.

6. The use of a combination of:

(A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and

(B) an insulin secretagogue,

in the manufacture of a medicament for prevention or treatment of diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are to be administered to a patient in need either simultaneously or separately.

7. The use according to claim 6, wherein the insulin secretagogue is glipizide, glibenclamide, and glimepiride.

8. The use according to claim 7, wherein the insulin secretagogue is glipizide or glimepiride.

9. The use according to claim 7, wherein the insulin secretagogue is glipizide.

10. The use according to claim 7, wherein the insulin secretagogue is glimepiride.

11. The use according to any one of claims 6 to 10, wherein diabetes mellitus is type 2 diabetes.

12. The use according to any one of claims 6 to 11, wherein the complication of diabetes mellitus is diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cerebrovascular disorder, ischemic cardiac disease, or peripheral arterial disease.